Anemias clinical trials
7 Anemias trials (Classical Hematology) summarized for fellows and board review, newest first within each disease. Each summary covers design, results, toxicity and what changed in practice.
Jump to: AIHA - warm · Iron deficiency · AIHA
AIHA - warm (3)
- ENERGY Blood 2026In the first randomised controlled trial in wAIHA, nipocalimab 30 mg/kg q4w met its primary endpoint for durable hemoglobin response, with nominal improvements in...
- RAIHA Am J Hematol 2017Rituximab combined with prednisone was significantly more effective than prednisone alone in achieving and maintaining response in first-line warm AIHA, with a...
- Birgens 2013 (Rituximab + prednisolone vs prednisolone, warm AIHA) Br J Haematol 2013Adding rituximab to prednisolone as first-line therapy for warm AIHA significantly increased the rate and duration of hematologic response compared to prednisolone...
Iron deficiency (3)
- AFFIRM-AHF Lancet 2020FCM narrowly missed the primary endpoint composite (P=.059) but significantly reduced total HF hospitalizations (P=.013), with COVID-19-related early stopping...
- PIVOTAL NEJM 2019High-dose proactive IV iron in hemodialysis was non-inferior and superior to low-dose reactive dosing for cardiovascular outcomes, while reducing ESA requirements...
- FAIR-HF NEJM 2009IV ferric carboxymaltose significantly improved patient global assessment, NYHA class, and exercise capacity in iron-deficient HF patients, with benefit in both...
AIHA (1)
- CARDINAL NEJM 2021Sutimlimab rapidly and substantially reduced hemolysis in CAD patients who had recently required transfusion, increasing hemoglobin, normalizing bilirubin, avoiding...